Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
KRRO
Upturn stock ratingUpturn stock rating

Frequency Therapeutics Inc (KRRO)

Upturn stock ratingUpturn stock rating
$12.49
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: KRRO (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

10 Analysts rated it

Well-followed company, solid analyst reports, reliable data for confident investing.

1 Year Target Price $101.83

1 Year Target Price $101.83

Analysts Price Target For last 52 week
$101.83Target price
Low$10.29
Current$12.49
high$98

Analysis of Past Performance

Type Stock
Historic Profit -65.03%
Avg. Invested days 21
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 112.97M USD
Price to earnings Ratio -
1Y Target Price 101.83
Price to earnings Ratio -
1Y Target Price 101.83
Volume (30-day avg) 10
Beta -
52 Weeks Range 10.29 - 98.00
Updated Date 06/30/2025
52 Weeks Range 10.29 - 98.00
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -9.42

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -981.18%

Management Effectiveness

Return on Assets (TTM) -29.82%
Return on Equity (TTM) -60.22%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 42917904
Price to Sales(TTM) 23.43
Enterprise Value 42917904
Price to Sales(TTM) 23.43
Enterprise Value to Revenue 8.9
Enterprise Value to EBITDA -5.6
Shares Outstanding 9390490
Shares Floating 4888127
Shares Outstanding 9390490
Shares Floating 4888127
Percent Insiders 6.19
Percent Institutions 104.41

Analyst Ratings

Rating 4
Target Price 101.83
Buy 4
Strong Buy 6
Buy 4
Strong Buy 6
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Frequency Therapeutics Inc

stock logo

Company Overview

overview logo History and Background

Frequency Therapeutics, Inc. was founded in 2014. It is a biotechnology company focused on developing new therapies to activate progenitor cells within the body to restore healthy tissue.

business area logo Core Business Areas

  • Hearing Loss Therapeutics: Developing novel regenerative therapies for hearing loss utilizing Progenitor Cell Activation (PCA) technology. Their lead product candidate is FX-322.

leadership logo Leadership and Structure

David Lucchino is the Chief Executive Officer. The company has a board of directors and operates with functional departments typical of a biotechnology company, including research, development, clinical operations, and finance.

Top Products and Market Share

overview logo Key Offerings

  • FX-322: FX-322 is Frequency Therapeutics' lead product candidate, an investigational locally administered drug designed to regenerate auditory hair cells within the cochlea for sensorineural hearing loss. As of December 2023, the company paused the development of FX-322 to focus on earlier stage assets. Competitors include companies developing gene therapies, cell therapies, and other small molecules for hearing loss (e.g., Decibel Therapeutics (DBTX)). Current FX-322 revenue is $0.

Market Dynamics

industry overview logo Industry Overview

The biotechnology industry is characterized by high risk and high reward. It is undergoing innovations in gene and cell therapies. The hearing loss therapeutics market is driven by the prevalence of hearing loss, an aging population, and technological advancements.

Positioning

Frequency Therapeutics aimed to be a leader in regenerative hearing loss therapies using their PCA platform. However, the clinical trial results led to them pausing development and seeking alternative approaches. Their positioning is now uncertain as they shift strategic direction.

Total Addressable Market (TAM)

The global hearing loss market is significant, estimated at billions of dollars annually. Frequency Therapeutics aimed to capture a portion of this market with FX-322. As they move into early assets, their position in the TAM needs to be re-evaluated.

Upturn SWOT Analysis

Strengths

  • Novel PCA technology platform
  • Experienced leadership team (prior to restructuring)
  • Strong intellectual property portfolio (patents surrounding PCA platform)

Weaknesses

  • Clinical trial failures of FX-322
  • Uncertainty regarding future strategic direction
  • Limited financial resources
  • Dependence on a single technology platform

Opportunities

  • Potential for strategic partnerships
  • Development of new PCA-based therapies
  • Exploration of other therapeutic areas for PCA technology
  • Future funding opportunities

Threats

  • Regulatory hurdles
  • Competition from other companies developing hearing loss therapies
  • Clinical trial failures of future product candidates
  • Patent challenges

Competitors and Market Share

competitor logo Key Competitors

  • DBTX

Competitive Landscape

Frequency Therapeutics faces competition from companies pursuing various approaches to treating hearing loss. The change in strategic direction impacts the current competitive landscape. The competitive landscape is uncertain as it pauses development of FX-322.

Growth Trajectory and Initiatives

Historical Growth: The historical growth was centered around the advancement of FX-322. The growth trajectory has been significantly impacted due to the recent shift in the strategic direction.

Future Projections: Future projections are highly uncertain given the strategic shift. Analyst estimates are likely to be revised.

Recent Initiatives: Recent strategic initiatives include pausing development of FX-322 and focusing on earlier stage assets.

Summary

Frequency Therapeutics faces significant challenges after pausing development of their lead candidate, FX-322. The company is now focused on early assets. The future direction is uncertain, and its success depends on its ability to develop and commercialize future therapies. Poor financials and clinical trial results have greatly affected the company. Competitor success is a potential threat to the future growth of the company.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Frequency Therapeutics Investor Relations
  • SEC Filings
  • Analyst Reports

Disclaimers:

The information provided is for informational purposes only and should not be considered as financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Frequency Therapeutics Inc

Exchange NASDAQ
Headquaters Cambridge, MA, United States
IPO Launch date 2023-11-06
CEO, President & Director Dr. Ram Aiyar MBA, Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 112
Full time employees 112

Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. Its lead product candidate is KRRO-110 which is in Phase 1/2 clinical trial for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe drug-associated anesthetics, and other pain indications. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.